翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序

智通財經

09/11

【翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序】智通財經APP訊，翰森製藥(03692.HK)發布公告，於2026年8月21日，基於注射用瑞康立伏妥塔單抗 (HS-20093)(該產品)關鍵性III期試驗ARTEMIS-008的積極結果，該產品用於經含鉑治療失敗的小細胞肺癌適應症納入中國國家藥品監督管理局(NMPA)優先審評審批程序。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/news/2666547845"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666547845\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666547845?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-11 16:33","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2666547845","market":"hk","top_or_hot":-1,"title":"翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序】</b>智通財經APP訊，翰森製藥(03692.HK)發布公告，於2026年8月21日，基於注射用瑞康立伏妥塔單抗 \n\n(HS-20093)(該產品)關鍵性III期試驗ARTEMIS-008的積極結果，該產品用於經含鉑治療失敗的小細胞肺癌適應症納入中國國家藥品監督管理局(NMPA)優先審評審批程序。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-09-11 16:33</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序】</b>智通財經APP訊，翰森製藥(03692.HK)發布公告，於2026年8月21日，基於注射用瑞康立伏妥塔單抗 \n\n(HS-20093)(該產品)關鍵性III期試驗ARTEMIS-008的積極結果，該產品用於經含鉑治療失敗的小細胞肺癌適應症納入中國國家藥品監督管理局(NMPA)優先審評審批程序。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2666547845","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666547845","pubTimestamp":1789115584,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序】智通財經APP訊，翰森製藥(03692.HK)發布公告，於2026年8月","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药"},"translate_title":"Hansoh Pharmaceuticals (03692.HK): Injectable Recanlivotuzumab (HS-20093) for the treatment of small cell lung cancer has been included in the priority review and approval procedure of the National Medical Products Administration.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1.5},"content_text":"【翰森製藥(03692.HK)：注射用瑞康立伏妥塔單抗(HS-20093)治療小細胞肺癌納入國家藥品監督管理局優先審評審批程序】智通財經APP訊，翰森製藥(03692.HK)發布公告，於2026年8月21日，基於注射用瑞康立伏妥塔單抗 \n\n(HS-20093)(該產品)關鍵性III期試驗ARTEMIS-008的積極結果，該產品用於經含鉑治療失敗的小細胞肺癌適應症納入中國國家藥品監督管理局(NMPA)優先審評審批程序。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}